United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

10:52am EDT
Change (% chg)

$-0.08 (-0.34%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Jensen, Peder 

Dr. Peder K. Jensen, M.D., is an Independent Director of Acorda Therapeutics, Inc., Dr. Jensen is currently president of Bay Way Consultants, LLC, a consulting firm founded by Dr. Jensen in 2010 that advises pharmaceutical and biotechnology companies. Dr. Jensen’s experience includes over 20 years with Schering-Plough Corporation, a global pharmaceutical company, and then Merck & Co., Inc. after the merger of Schering-Plough with Merck in 2009. During his tenure at Schering-Plough/Merck, Dr. Jensen held a number of global senior research and development positions, including Vice President Clinical Research, SPRI, Executive Vice President Worldwide Drug Development, SPRI, and most recently Corporate Senior Vice President, and General Manager, R&D for Japan and Asia/Pacific from 2006 to 2010. Dr. Jensen has more than 24 years of global drug development experience across a variety of therapeutic areas, including neurology, cardiovascular, anti-infective, oncology and immunology. Over the course of his career, Dr. Jensen has been responsible for more than 40 new drug approvals worldwide, including in the U.S., Europe and Japan. Dr. Jensen also currently serves on the board of directors of Five Prime Therapeutics, Inc. Dr. Jensen previously was a member of the board of directors of BioCryst Pharmaceuticals, Inc. Dr. Jensen received his M.D. from the University of Copenhagen.

Basic Compensation

Total Annual Compensation, USD 76,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 178,766
Fiscal Year Total, USD 254,766

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen


Richard Batycky


David Lawrence


Andrew Blight


Jane Wasman


Burkhard Blank

As Of  30 Dec 2016